0000899243-18-008659.txt : 20180327
0000899243-18-008659.hdr.sgml : 20180327
20180327182527
ACCESSION NUMBER: 0000899243-18-008659
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180327
FILED AS OF DATE: 20180327
DATE AS OF CHANGE: 20180327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novartis Institutes for BioMedical Research, Inc.
CENTRAL INDEX KEY: 0001673852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38433
FILM NUMBER: 18716650
BUSINESS ADDRESS:
STREET 1: 250 MASSACHUSETTS AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (617) 871-8000
MAIL ADDRESS:
STREET 1: 250 MASSACHUSETTS AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NOVARTIS AG
CENTRAL INDEX KEY: 0001114448
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38433
FILM NUMBER: 18716649
BUSINESS ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
BUSINESS PHONE: 01141613241111
MAIL ADDRESS:
STREET 1: LICHTSTRASSE 35
CITY: BASEL
STATE: V8
ZIP: CH 4056
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Homology Medicines, Inc.
CENTRAL INDEX KEY: 0001661998
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473468154
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 WIGGINS AVE.
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: 45 WIGGINS AVE.
CITY: BEDFORD
STATE: MA
ZIP: 01730
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-03-27
0
0001661998
Homology Medicines, Inc.
FIXX
0001673852
Novartis Institutes for BioMedical Research, Inc.
250 MASSACHUSETTS AVENUE
CAMBRIDGE
MA
02139
0
0
1
0
0001114448
NOVARTIS AG
LICHTSTRASSE 35
BASEL
V8
CH 4056
SWITZERLAND
0
0
1
0
Series B Preferred Stock
Common Stock
1979226
D
The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI.
Novartis Institutes for BioMedical Research, Inc., By: /s/ Scott A. Brown, VP, General Counsel
2018-03-27
Novartis AG, By: /s/ Stefan Thommen, Authorized Signatory, By: /s/ Susan Jones, Authorized Signatory
2018-03-27